8-K: Instil Bio In-Licenses Two Cancer Drugs, Leases Manufacturing Facility to AstraZeneca, Bolstering Financial Position

Instil Bio has expanded its pipeline with two in-licensed cancer drugs and secured a 15-year lease for its manufacturing facility, extending its cash runway beyond 2026.

Summary

• Instil Bio reported its financial results for the second quarter of 2024 and provided a corporate update.
• The company in-licensed two potentially best-in-class clinical-stage therapeutics: SYN-2510, a PD-L1xVEGF bispecific antibody, and SYN-27M, an ADCC-enhanced anti-CTLA-4 antibody.
• Instil also entered into a 15-year lease agreement with AstraZeneca for its cell therapy manufacturing facility in Tarzana, California.
• The lease provides Instil with an initial base rent of over $7.5 million annually, escalating at 3% per year.
• As of June 30, 2024, Instil had $152.6 million in cash, cash equivalents, marketable securities, and long-term investments.
• The company expects its current financial resources to fund its operating plan beyond 2026.
• Research and development expenses for Q2 2024 were $2.9 million, down from $8.5 million in Q2 2023.
• General and administrative expenses for Q2 2024 were $10.7 million, compared to $11.5 million in Q2 2023.
• Net loss for Q2 2024 was $14.9 million, or $2.29 per share, compared to a net loss of $18.7 million, or $2.87 per share, in Q2 2023.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the in-licensing of promising assets and the securing of a long-term lease agreement. However, the company's ongoing net loss and the inherent risks of drug development temper the overall sentiment.

Positives

• Strengthened pipeline with the addition of two promising clinical-stage assets.
• Secured a long-term lease agreement for its manufacturing facility, providing a stable revenue stream.
• Reduced research and development expenses compared to the same period last year.
• Maintains a strong cash position to support ongoing operations and clinical development.

Negatives

• Net loss for the second quarter of 2024 was $14.9 million.
• General and administrative expenses remained relatively high at $10.7 million for the quarter.
• Incurred restructuring and impairment charges of $0.5 million in Q2 2024.

Risks

• The development of SYN-2510 and SYN-27M is subject to the inherent risks and uncertainties of the drug development process, including the possibility of unfavorable clinical trial results.
• Reliance on collaborators and other third parties for manufacturing and generating clinical data.
• The ability to rely on any such data from clinical trials in China in regulatory filings submitted to regulatory authorities outside of China.
• The uncertainty of regulatory approval for its product candidates.
• Potential impact of macroeconomic conditions, including international conflicts and U.S.-China trade and political tensions, on the company's business and operations.
• The sufficiency of cash resources to fund operations and development programs.

Future Outlook

Instil Bio's current cash position is expected to fund its operating plan beyond 2026. The company is exploring further opportunities to in-license or acquire novel therapeutic candidates.

Management Comments

• 'We have expanded our pipeline with a pair of clinical-stage, potentially best-in-class therapeutics by in-licensing SYN-2510 and SYN-27M,' said Bronson Crouch, CEO of Instil.
• 'By executing a 15-year lease of our Tarzana cell therapy manufacturing facility, we have strengthened our financial foundation to support Instils near-term clinical development of these assets.'

Industry Context

The announcement reflects the growing interest in novel immunotherapies for cancer treatment, particularly bispecific antibodies and ADCC-enhanced antibodies. The in-licensing of SYN-2510 and SYN-27M positions Instil to compete in this rapidly evolving landscape.

Comparison to Industry Standards

• Instil's in-licensing of SYN-2510, a PD-L1xVEGF bispecific antibody, is similar to other deals in the industry, such as Roche's acquisition of TeneoBio, which included a similar bispecific antibody targeting PD-L1 and VEGF.
• Compared to Iovance Biotherapeutics, a competitor in the cell therapy space, Instil's approach of in-licensing clinical-stage assets may allow for faster development timelines.
• Instil's net loss of $14.9 million for Q2 2024 is not unusual for a clinical-stage biopharmaceutical company. For example, Iovance Biotherapeutics reported a net loss of $108.5 million in the same period, and Adaptimmune Therapeutics reported a net loss of $42.4 million.
• Instil's cash position of $152.6 million is relatively strong compared to some other clinical-stage biotech companies. However, it is lower than that of larger, more established companies in the space.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the in-licensed assets are successfully developed and commercialized.
• Employees: Potential for new job opportunities as the company expands its pipeline and operations.
• Customers: Potential for new and improved cancer treatments if the in-licensed assets are successful.
• Suppliers: Potential for increased business opportunities as the company advances its development programs.
• Creditors: The long-term lease agreement provides a stable revenue stream, potentially reducing credit risk.

Next Steps

• Continue clinical development of SYN-2510 and SYN-27M.
• Explore further opportunities to in-license or acquire novel therapeutic candidates.
• Continue patient enrollment in Phase 1a dose escalation studies for SYN-2510 and SYN-27M in China.
• Support dose optimization and dose expansion for SYN-2510 and SYN-27M.

Key Dates

Keywords

Instil Bio, biopharmaceutical, cancer therapy, immunotherapy, PD-L1xVEGF bispecific antibody, SYN-2510, ADCC-enhanced anti-CTLA-4 antibody, SYN-27M, ImmuneOnco, cell therapy manufacturing, AstraZeneca, in-licensing, clinical trials, solid tumors, oncology